专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO9739722A3 Method of isolating regulations of T cell activation 审中-公开
标题翻译：分离T细胞活化规则的方法
公开(公告)号：WO9739722A3
公开(公告)日：1998-07-16
申请号：PCT/US9707052
申请日：1997-04-25
申请人： T CELL SCIENCES INC , LIN AUGUSTINE Y , UMLAUF SCOTT W , BATZER ANDREAS G
发明人： LIN AUGUSTINE Y , UMLAUF SCOTT W , BATZER ANDREAS G
IPC分类号： C07K14/47 , C12Q1/68 , G01N33/50 , A61K31/38 , A61K31/165 , A61K31/495
CPC分类号： C12Q1/6897 , C07K14/47 , C07K14/4702 , G01N33/505
摘要： This invention provides a multi-step, high throughput primary screen to identify immune regulators of T cell activation for use as therapeutic agents. Compositions or compounds are screened for their ability to stimulate or inhibit the expression of a reporter gene operatively linked to specific transcriptional control sequences in T cells. A composition or compound identified as an immune stimulator or inhibitor by the primary screen of this invention can then be further characterized to determine the target molecule on which the composition or compound acts to regulate T cell activation and T cell activation-dependent processes such as apoptosis.

22. 发明申请

WO1995016038A2 HUMANIZED ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：人类抗体及其用途
公开(公告)号：WO1995016038A2
公开(公告)日：1995-06-15
申请号：PCT/IB1994000387
申请日：1994-11-21
申请人： T CELL SCIENCES, INC. , MERCER, Christopher, Paul , LIN, Augustine, Yee-Tharn
发明人： T CELL SCIENCES, INC. , MERCER, Christopher, Paul
IPC分类号： C12N15/13
CPC分类号： C07K16/2809 , A61K38/00
摘要： The present invention relates to humanized antibodies and binding proteins thereof, capable of binding to T cells exhibiting particular variable beta chains, and particularly those subpopulations expressing human V beta 5.2 and/or 5.3, and V beta 8.1. The present invention also relates to the preparation of such antibodies, to pharmaceutical compositions containing them, and therapeutic utilization of the antibodies, specifically in autoimmune diseases.
摘要翻译：本发明涉及能够结合表现出特定可变β链的T细胞的人源化抗体及其结合蛋白，特别是涉及表达人V beta 5.2和/或5.3以及Vβ1B的那些亚群。本发明还涉及这种抗体的制备，含有它们的药物组合物，以及抗体的治疗性利用，特别是在自身免疫性疾病中。

23. 发明申请

WO1994026786A1 COMPOSITIONS COMPRISING COMPLEMENT RELATED PROTEINS AND CARBOHYDRATES, AND METHODS FOR PRODUCING AND USING SAID COMPOSITIONS 审中-公开
标题翻译：包含相关蛋白质和碳水化合物的组合物，以及用于生产和使用上述组合物的方法
公开(公告)号：WO1994026786A1
公开(公告)日：1994-11-24
申请号：PCT/US1994005285
申请日：1994-05-12
申请人： T CELL SCIENCES, INC. , RITTERSHAUS, Charles, W. , TOTH, Carol, A.
发明人： T CELL SCIENCES, INC.
IPC分类号： C07K15/14
CPC分类号： C07K14/7056 , A61K38/00 , C07K14/705
摘要： The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.
摘要翻译：本发明提供了包含至少一个补体部分和至少一个碳水化合物部分的组合物，以及生产这种组合物的方法。特别地，本发明的组合物包含与1型补体受体相关的补体蛋白，并且还包含细胞内分子例如选择素的配体。在优选的实施方案中，组合物包含与Lewis X抗原或唾液酸基路易斯X抗原组合的补体相关蛋白。本发明的组合物可用于诊断或治疗涉及补体活性和炎症的疾病。还提供药物组合物用于治疗或减少由不适当的补体活性和细胞间粘附介导的炎症。

24. 发明申请

WO1994010571A1 MEASUREMENT OF TOTAL MOLECULE IN A SAMPLE AND METHODS BASED THEREON 审中-公开
标题翻译：基于该方法测定总分子量和方法
公开(公告)号：WO1994010571A1
公开(公告)日：1994-05-11
申请号：PCT/US1993010550
申请日：1993-10-29
申请人： T CELL SCIENCES, INC. , T CELL DIAGNOSTICS, INC. , RITTERSHAUS, Charles, W. , KUNG, Patrick, C. , PARSONS, George, H. , MEISNER, Patricia, S. , FOX, Alfred, E.
发明人： T CELL SCIENCES, INC. , T CELL DIAGNOSTICS, INC.
IPC分类号： G01N33/53
CPC分类号： C12Q1/6806 , C12Q1/6886 , C12Q2600/106 , G01N33/569 , G01N33/56911 , G01N33/56972 , G01N33/56983 , G01N33/571 , G01N33/6863
摘要： The measurement of the total amount of a target molecule is used in the detection, diagnosis, determining the severity of and staging of a variety of diseases or disorders and the monitoring of therapy. The measurements of the total amount of a target molecule is accomplished by treating a sample containing cells, such as a body fluid, with a non-ionic detergent in a manner that makes available for binding to one or more binding partners the total amount of a target molecule present in the cell membrane, the cytoplasm of the cell and/or in the soluble compartments of the body fluid. Once the total target molecule is available, it is measured using any of a number of assay techniques, preferably by sandwich enzyme immunoassay. The methods of the present application may be used to detect and measure molecules associated with microbial pathogens, in particular intracellular pathogens such as Chlamydia, as well as erythrocyte blood group antigens, tumor antigens, cytokines and cell adhesion molecules, for diagnosis, enumeration of cells expressing such molecules, and other methods.
摘要翻译：靶分子总量的测定用于检测，诊断，确定各种疾病或病症的严重性和分期以及对治疗的监测。靶分子的总量的测量是通过用非离子型洗涤剂处理含有细胞例如体液的样品，以使得可以与一种或多种结合配偶体结合的方式完成存在于细胞膜中的靶分子，细胞的细胞质和/或体液的可溶性隔室中。一旦总靶分子可用，就可以使用多种测定技术中的任何一种来测量，优选通过夹心酶免疫测定法。本申请的方法可用于检测和测量与微生物病原体特别是细胞内病原体如衣原体相关的分子，以及红细胞血型抗原，肿瘤抗原，细胞因子和细胞粘附分子，用于诊断，细胞计数表达这种分子等方法。

25. 发明申请

WO1992010096A1 COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY 审中-公开
标题翻译：禁止补充和/或抑制免疫活性的化合物
公开(公告)号：WO1992010096A1
公开(公告)日：1992-06-25
申请号：PCT/US1991009303
申请日：1991-12-06
申请人： T CELL SCIENCES, INC. , THE UNIVERSITY OF MISSISSIPPI , SINDELAR, Robert, D. , BRADBURY, Barton, J. , KAUFMAN, Teodoro, S. , IP, Stephen, H. , MARSH, Henry, C., Jr. , LEE, Chew
发明人： T CELL SCIENCES, INC. , THE UNIVERSITY OF MISSISSIPPI
IPC分类号： A01N43/08
CPC分类号： C07D307/94
摘要： The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.
摘要翻译：本发明涉及抑制免疫应答和/或选择性抑制补体的化合物。这些化合物含有芳环，是取代的二氢苯并呋喃，螺苯并呋喃-2（3H） - 环烷及其开链中间体。本发明的化合物及其药学上可接受的盐中断了C5对生物活性成分的蛋白水解加工，表现出免疫抑制活性，并且具有改善由补体和/或免疫活性介导的疾病和病症的治疗效用。

26. 发明申请

WO1990006758A1 MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN RECEPTOR 审中-公开
标题翻译：与细胞抗原受体的定义区域反应的单克隆抗体
公开(公告)号：WO1990006758A1
公开(公告)日：1990-06-28
申请号：PCT/US1989005601
申请日：1989-12-14
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , SKIBBENS, Robert, V. , HENRY, Larry, D. , RITTERSHAUS, Charles, W. , TIAN, Wei-Tao , IP, Stephen, H. , KUNG, Patrick, C. , SNIDER, Mary, Ellen , KO, Jone-Long , WOOD, Nancy, L.
IPC分类号： A61K35/14
CPC分类号： C07K16/2809 , A61K38/00 , A61K2039/505 , C07K2317/74 , Y10S436/804 , Y10S436/811
摘要： The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed αF1 and αF2, which react with two different epitopes on the framework region of the α monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with β chain variable regions Vβ5.3 and Vβ8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody δTCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

27. 发明申请

WO1990004180A1 THERAPEUTIC AND DIAGNOSTIC METHODS USING SOLUBLE T CELL SURFACE MOLECULES 审中-公开
标题翻译：使用可溶性T细胞表面分子的治疗和诊断方法
公开(公告)号：WO1990004180A1
公开(公告)日：1990-04-19
申请号：PCT/US1989004413
申请日：1989-10-05
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , KUNG, Patrick, C. , IP, Stephen, H. , BROWN, Michael, C. , MACKEEN, Linda, A.
IPC分类号： G01N33/535
CPC分类号： C07K16/2812 , C07K16/2815 , G01N33/564 , G01N33/56977 , G01N33/56988 , G01N33/57488 , G01N33/6869 , G01N2333/71 , G01N2800/102 , G01N2800/245
摘要： The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. Specific embodiments involve the diagnosis and monitoring of therapy using absolute values of such soluble molecules. Further embodiments involve detecting a change in the levels of such soluble molecules, in the diagnosis and therapy of diseases and disorders. In specific embodiments, detection of increases in both soluble IL2R and creatinine in the body fluid of a transplant patient can be used to differentially diagnose renal allograft rejection from infection. The invention is also directed to methods for measurement of soluble CD4 antigens, which measurements can be used, in a specific embodiment, to diagnose a state of immune activation, to diagnose rheumatoid arthritis, or to stage adult T cell leukemia in a patient. In another embodiment, soluble CD4 levels can be used to monitor the efficacy of disease treatments, a specific embodiment including monitoring therapy of HIV-infected patients. In another aspect, the invention relates to the detection, staging, or monitoring of therapy of diseases and disorders by measuring a plurality of soluble T cell markers.
摘要翻译：本发明涉及可溶性T细胞生长因子受体，可溶性T细胞分化抗原或相关的可溶性分子或其片段的测量，以及这些测量在疾病和病症的诊断和治疗中的应用。具体实施方案涉及使用这种可溶性分子的绝对值来诊断和监测治疗。进一步的实施方案涉及在疾病和病症的诊断和治疗中检测这些可溶性分子的水平的变化。在具体实施方案中，移植患者的体液中可溶性IL2R和肌酐两者的增加的检测可用于差异诊断感染的肾同种异体移植物排斥反应。本发明还涉及用于测量可溶性CD4抗原的方法，在具体实施方案中可以使用该测量来诊断患者的免疫激活状态，诊断类风湿性关节炎或阶段性成年T细胞白血病。在另一个实施方案中，可溶性CD4水平可用于监测疾病治疗的功效，一个具体实施方案包括监测HIV感染患者的治疗。另一方面，本发明涉及通过测量多种可溶性T细胞标记来检测，分期或监测疾病和病症的治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式